This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
by Zacks Equity Research
Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.
Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval
by Zacks Equity Research
Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.
Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study
by Zacks Equity Research
Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.
Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late
by Zacks Equity Research
Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.
Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent
by Zacks Equity Research
Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.
The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron
Top Research Reports for Target, Illumina & T-Mobile US
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Target (TGT), Illumina (ILMN) and T-Mobile US (TMUS).
Alnylam Focuses on Pipeline Development Amid Competition
by Zacks Equity Research
Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.
Alnylam Begins Phase III Study on Onpattro for New Indication
by Zacks Equity Research
Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.
Aimmune's Peanut Allergy Drug Gets FDA Committee's Support
by Zacks Equity Research
Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.
Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use
by Zacks Equity Research
Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.
Adverum Reports Data From Phase I Wet AMD Study, Stock Down
by Zacks Equity Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe
by Zacks Equity Research
The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
Regeneron (REGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
by Ekta Bagri
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.
Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
by Zacks Equity Research
A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.
Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent.
Inovio (INO) Down More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.
Esperion's Drugs in Review Hold Potential, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100
by Zacks Equity Research
Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
Top Analyst Reports for Estee Lauder, Becton, Dickinson & Applied Materials
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Estee Lauder (EL), Becton, Dickinson (BDX) and Applied Materials (AMAT).